Taking aim at disease

February 16, 2024, 3:02PMNuclear NewsKristi Nelson Bumpus
ORNL radioisotope manufacturing coordinator Jillene Sennon-Greene places a shipment vial of actinium-225 inside the dose calibrator to confirm its activity is within customer specifications. (Photo: Carlos Jones/ORNL, DOE)

On August 2, 1946, 1 millicurie of the isotope carbon-14 left Oak Ridge National Laboratory, bound for the Barnard Free Skin and Cancer Hospital in St. Louis, Mo.

That tiny amount of the radioisotope was purchased by the hospital for use in cancer studies. And it heralded a new peacetime mission for ORNL, built just a few years earlier for the production of plutonium from uranium for the Manhattan Project.

To continue reading, log in or create a free account!

Related Articles

The current status of heat pipe R&D

October 10, 2025, 4:42PMNuclear NewsIlyas Yilgor, Mauricio Tano, Katrina Sweetland, Joshua Hansel, and Piyush Sabharwall

Idaho National Laboratory under the Department of Energy–sponsored Microreactor Program recently conducted a comprehensive phenomena identification and ranking table (PIRT) exercise aimed at...